Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014, Meldola, FC, Italy.
Istituto Nazionale di Fisica Nucleare, Sezione di Bologna, 40126, Bologna, Italy.
Sci Rep. 2022 Jan 7;12(1):14. doi: 10.1038/s41598-021-03807-6.
The majority of local recurrences, after conservative surgery of breast cancer, occurs in the same anatomical area where the tumour was originally located. For the treatment of ductal carcinoma in situ (DCIS), a new medical device, named BAT-90, (BetaGlue Technologies SpA) has been proposed. BAT-90 is based on the administration of Y β-emitting microspheres, embedded in a bio-compatible matrix. In this work, the Geant4 simulation toolkit is used to simulate BAT-90 as a homogenous cylindrical Y layer placed in the middle of a bulk material. The activity needed to deliver a 20 Gy isodose at a given distance z from the BAT-90 layer is calculated for different device thicknesses, tumour bed sizes and for water and adipose bulk materials. A radiobiological analysis has been performed using both the Poisson and logistic Tumour Control Probability (TCP) models. A range of radiobiological parameters (α and β), target sizes, and densities of tumour cells were considered. Increasing α values, TCP increases too, while, for a fixed α value, TCP decreases as a function of clonogenic cell density. The models predict very solid results in case of limited tumour burden while the activity/dose ratio could be further optimized in case of larger tumour beds.
大多数乳腺癌保乳手术后的局部复发发生在肿瘤最初所在的同一解剖区域。为了治疗导管原位癌(DCIS),一种名为 BAT-90 的新医疗器械(BetaGlue Technologies SpA)已被提出。BAT-90 基于 Yβ发射微球的给药,嵌入在生物相容的基质中。在这项工作中,Geant4 模拟工具包用于模拟 BAT-90 作为同质圆柱形 Y 层,放置在大块材料的中间。对于不同的设备厚度、肿瘤床大小以及水和脂肪体材料,计算了在距 BAT-90 层给定距离 z 处输送 20Gy 等剂量所需的活性。使用泊松和逻辑肿瘤控制概率(TCP)模型进行了放射生物学分析。考虑了一系列放射生物学参数(α和β)、靶标大小和肿瘤细胞密度。随着α值的增加,TCP 也会增加,而对于固定的α值,随着克隆形成细胞密度的增加,TCP 会降低。在肿瘤负担有限的情况下,这些模型预测结果非常可靠,而在肿瘤床较大的情况下,可以进一步优化活性/剂量比。